Literature DB >> 11786411

Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays.

Axel Hoos1, Alexander Stojadinovic, Bhuvanesh Singh, Maria E Dudas, Denis H Y Leung, Ashok R Shaha, Jatin P Shah, Murray F Brennan, Carlos Cordon-Cardo, Ronald Ghossein.   

Abstract

Hürthle cell tumors are rare thyroid neoplasms for which disease biology is poorly understood and diagnosis of carcinoma can be challenging. The aim of the study was to characterize molecular expression profiles of Hürthle cell tumors and to determine the clinical significance of identified phenotypes. Paraffin-embedded tissue cores of normal thyroid (n = 18), and histopathologically well-defined Hürthle cell adenomas (n = 27), Hürthle cell tumors of unknown malignant behavior (n = 7), and minimally (n = 14) and widely (n = 21) invasive Hürthle cell carcinomas were arrayed in triplicate on tissue microarrays. Expression profiles of p53, mdm-2, p21, Bcl-2, cyclin D1, and Ki-67 were detected by immunohistochemistry and correlated with clinicopathological data and patient outcome using standard statistical methodology. Median follow-up time was 8 years. High Ki-67 proliferative index was evident only in the clinically aggressive widely invasive Hürthle cell carcinomas and was associated with significantly reduced relapse-free (P = 0.001) and disease-specific (P < 0.001) survival. The molecular phenotype of Hürthle cell tumors, independent of histopathological subtype diagnosis, was characterized by p53(-), mdm-2(+), p21(+/-), cyclin D1(-), and Bcl-2(+/-). Normal thyroid tissue demonstrated a p53(-), mdm-2(-), p21(-), cyclin D1(-), and Bcl-2(+) phenotype. The Bcl-2(+) phenotype was associated with improved relapse-free survival (P = 0.04) and disease-specific survival (P = 0.01) in widely invasive carcinomas and the Ki-67(+)/Bcl-2(-) phenotype was associated with the diagnosis of widely invasive Hürthle cell carcinoma (P < 0.001). This study demonstrates that tissue microarray-based profiling allows identification of molecular markers that are associated with patient prognosis. High Ki-67 proliferative index was associated with adverse outcome in Hürthle cell neoplasms. Together with down-regulation of Bcl-2, high Ki-67 proliferative index may be useful for diagnosing widely invasive Hürthle cell carcinomas. Molecular alterations in the p53 pathway play a role in Hürthle cell tumorigenesis, but other unidentified molecular changes seem to be required to induce the malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11786411      PMCID: PMC1867123          DOI: 10.1016/S0002-9440(10)64361-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Tumor cell proliferation and survival in patients with prostate cancer followed expectantly.

Authors:  M Borre; S M Bentzen; B Nerstrøm; J Overgaard
Journal:  J Urol       Date:  1998-05       Impact factor: 7.450

Review 2.  BCL-2 family: regulators of cell death.

Authors:  D T Chao; S J Korsmeyer
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

3.  Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis.

Authors:  A Molino; R Micciolo; M Turazza; F Bonetti; Q Piubello; A Bonetti; R Nortilli; G Pelosi; G L Cetto
Journal:  Int J Cancer       Date:  1997-08-22       Impact factor: 7.396

4.  Bcl-2 and Bax function independently to regulate cell death.

Authors:  C M Knudson; S J Korsmeyer
Journal:  Nat Genet       Date:  1997-08       Impact factor: 38.330

5.  Cyclin D1 and Cyclin E expression in malignant thyroid cells and in human thyroid carcinomas.

Authors:  D Lazzereschi; L Sambuco; C Carnovale Scalzo; A Ranieri; G Mincione; F Nardi; G Colletta
Journal:  Int J Cancer       Date:  1998-06-10       Impact factor: 7.396

6.  Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines.

Authors:  G H Jossart; H D Epstein; J K Shaver; H U Weier; K M Greulich; S Tezelman; R F Grossman; A E Siperstein; Q Y Duh; O H Clark
Journal:  J Clin Endocrinol Metab       Date:  1996-10       Impact factor: 5.958

7.  Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma.

Authors:  S K Grebe; B McIver; I D Hay; P S Wu; L M Maciel; H A Drabkin; J R Goellner; C S Grant; R B Jenkins; N L Eberhardt
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

8.  Expression of the retinoblastoma protein is regulated in normal human tissues.

Authors:  C Cordon-Cardo; V M Richon
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

Review 9.  Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia.

Authors:  C Cordon-Cardo
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

10.  Tissue microarrays for high-throughput molecular profiling of tumor specimens.

Authors:  J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

View more
  13 in total

1.  Expression of p63 and Bcl-2 in Malignant Thyroid Tumors and their Correlation with other Diagnostic Immunocytochemical Markers.

Authors:  Ashumi Gupta; Shyama Jain; Nita Khurana; Arun Kumar Kakar
Journal:  J Clin Diagn Res       Date:  2016-07-01

Review 2.  Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Authors:  Michael Shawky; Mahmoud Sakr
Journal:  Indian J Surg       Date:  2015-10-30       Impact factor: 0.656

Review 3.  Hurthle cell carcinoma of the thyroid.

Authors:  Mark Anthony S Sandoval; Elizabeth Paz-Pacheco
Journal:  BMJ Case Rep       Date:  2011-02-09

4.  Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.

Authors:  Nobuki Nakamura; Lori A Erickson; Long Jin; Sabine Kajita; Heyu Zhang; Xiang Qian; Kandelaria Rumilla; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

5.  Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid.

Authors:  Yi Wei Zhang; David Yu Greenblatt; Daniel Repplinger; Anna Bargren; Joel T Adler; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2008-07-30       Impact factor: 5.344

6.  Targeted therapies in thyroid cancer.

Authors:  Jaume Capdevila; Jose Perez-Garcia; Gabriel Obiols; Josep Tabernero
Journal:  Target Oncol       Date:  2009-11-11       Impact factor: 4.493

7.  Multiplexed and reiterative fluorescence labeling via DNA circuitry.

Authors:  Dzifa Y Duose; Ryan M Schweller; Walter N Hittelman; Michael R Diehl
Journal:  Bioconjug Chem       Date:  2010-11-16       Impact factor: 4.774

8.  A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping.

Authors:  Krzysztof Fujarewicz; Michal Jarzab; Markus Eszlinger; Knut Krohn; Ralf Paschke; Małgorzata Oczko-Wojciechowska; Małgorzata Wiench; Aleksandra Kukulska; Barbara Jarzab; Andrzej Swierniak
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

9.  Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration.

Authors:  André Ferreira-da-Silva; Cristina Valacca; Elisabete Rios; Helena Pópulo; Paula Soares; Manuel Sobrinho-Simões; Luca Scorrano; Valdemar Máximo; Silvia Campello
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

10.  Absent CD56 expression in papillary thyroid carcinoma: A finding of potential diagnostic value in problematic cases of thyroid pathology.

Authors:  Mozhgan Mokhtari; Mehdi Eftekhari; Reza Tahririan
Journal:  J Res Med Sci       Date:  2013-12       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.